Engineered CD3 antibodies for immunosuppression

Clinical and Experimental Immunology

Volumn 133, Issue 3, 2003, Pages 307-309

  Renders, L ^a   Valerius, Thomas ^a,b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b Division of Nephrology   (Germany)

Author keywords

Antibody; Antibody engineering; CD3; Immunosuppression; Transplantation

Indexed keywords

FC RECEPTOR; MONOCLONAL ANTIBODY CD3; OKT 3;

ANTIBODY ENGINEERING; CYTOTOXICITY; EDITORIAL; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; QUALITY OF LIFE; RECEPTOR BINDING; SURVIVAL; T LYMPHOCYTE;

ANTIGENS, CD3; AUTOIMMUNE DISEASES; GRAFT REJECTION; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOSUPPRESSIVE AGENTS; MUROMONAB-CD3; ORGAN TRANSPLANTATION; RECEPTORS, FC; TRANSPLANTATION, HOMOLOGOUS;

EID: 0042827679     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2003.02227.x     Document Type: Editorial

References (30)

1. Chatenaud L. Monoclonal antibodies in transplantation. Austin: R.G. Landes Company, 1995.
2. Waldmann H. Therapeutic approaches for transplantation. Curr Opin Immunol 2001; 13:606-10.
3. Wilde MI, Goa KL. Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drugs 1996; 51:865-94.
4. Meijer RT, Surachno S, Yong SL et al. Treatment of acute kidney allograft rejection with a nonmitogenic CD3 antibody (immunosuppression with IgA-CD3). Clin Exp Immunol; 2003; 133:486-93.
5. Herold KC, Burton JB, Francois F et al. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3γ1 (Ala-Ala). J Clin Invest 2003; 111:409-17.
6. 2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb. Transplantation 1990; 49:1117-23.
7. Raasveld MHM, Bemelmann FJ, Schellekens PTA et al. Complement activation during OKT3 treatment: a possible explanation for respiratory side effects. Kidney Int 1993; 43:1140-9.
8. Chatenaud L, Ferran C, Reuter A et al. Systemic reaction to the anti-T cell monclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-γ. N Eng J Med 1989; 320:1420-1.
9. Tax WJM, Willems HW, Reekers PPM et al. Polymorphism in mitogenic effect of IgG1 monoclonal antibodies against T3 antigen on human T cells. Nature 1983; 304:445-7.
10. van Sorge NM, van der Pol WL, van de Winkel JGJ. FcγR polymorphisms. implications for function, disease susceptibility and immunotherapy. Tissue Antigens 2002; 61:189-202.
11. Tax WJ, Tamboer WP, Jacobs CW et al. Role of polymorphic Fc receptor FcγRIIa in cytokine release and adverse effects of murine IgG1 anti-CD3/T cell receptor antibody (WT31). Transplantation 1997; 63:106-12.
12. Sondermann P, Kaiser J, Jacob U. Molecular basis for immune complex recognition. a comparison of Fc receptor structures. J Mol Biol 2001; 309:737-49.
13. Shields RL, Namenuk AK, Hong K et al. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of human IgG1 variants with improved binding to the FcγR. J Biol Chem 2000; 276:6591-604.
14. Abbs IC, Clark M, Waldmann H et al. Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with a diminished release of pro-inflammatory cytokines. J Ther Immunol 1994; 325: 1994.
15. Dechant M, Valerius T. IgA antibodies for tumor therapy. Crit Rev Oncol Hematol 2001; 39:69-77.
16. Jefferis R, Lund J, Pound JD. IgG-Fc-mediated effector functions. molecular definition of interaction sites for effector ligands and the role of glycosylation. Immunol Rev 1998; 163:59-76.
17. Wright A, Morrison SL. Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of chinese hamster ovary cells. J Immunol 1998; 160:3393-402.
18. Bolt S, Routledge E, Lloyd I et al. The generation of a humanized, nonmitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 1993; 23:403-11.
19. Friend PJ, Hale G, Chatenoud L et al. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation 1999; 68:1632-7.
20. Cole MS, Anasetti C, Tso JY. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells. J Immunol 1997; 159:3613-21.
21. Carpenter PA, Appelbaum FR, Corey L et al. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 2002; 99:2712-9.
22. Norman DJ, Vincenti F, de Mattos AM et al. Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors. Transplantation 2000; 70:1707-12.
23. Xu D, Alegre ML, Varga SS. In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol 2000; 200:16-26.
24. Smith JA, Tso JY, Clark MR et al. Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy. J Exp Med 1997; 185:1413-22.
25. Smith JA, Tang Q, Bluestone JA. Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets. J Immunol 1998; 160:4841-9.
26. Woodle ES, Xu D, Zivin RA et al. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3γ1 (Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 1999; 68:608-16.
27. Utset TO, Auger J, Peace D et al. Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol 2002; 29:1907-13.
28. Herold KC, Hagopian W, Auger JA et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346:1692-8.
29. Waldmann H, Cobbold S. How do monoclonal antibodies induce tolerance? A role for infectious tolerance ? Annu Rev Immunol 1998; 16:619-44.
30. Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol 2003; 3:123-32.